<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000442.v1.p1" parentStudy="phs000442.v1.p1" createDate="2011-12-07" modDate="2012-04-10">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Donna Arnett, PhD</td><td>University of Alabama at Birmingham, Birmingham, AL, USA</td></tr>
		<tr><td>Funding Source</td><td>NHLBI/NHGRI Exome Project</td><td>National Institutes of Health, Bethesda, MD, USA</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>Drug Resistant Hypertension in African Americans&#39; Exome</StudyNameEntrez>
	<StudyNameReportPage>Drug Resistant Hypertension in African Americans&#39; Exome</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Longitudinal</StudyType>
		<StudyType>Case Set</StudyType>
		<StudyType>Exome Sequencing</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Resistant hypertension is defined as blood pressure that remains above goal in spite of the concurrent use of 3 antihypertensive agents of different classes or the concurrent use of 4 or more antihypertensive agents regardless of control. Its diagnosis is important for the identification of patients who are at high risk of having reversible causes of hypertension and/or patients who, because of persistently high blood pressure levels, may benefit from special diagnostic and therapeutic considerations. Resistant hypertension represents an extreme phenotype, thus, it has been predicted that genetic factors could play a larger role than for the general hypertensive population. Genetic assessments of patients with resistant hypertension have been limited. The current study assayed the exome of 91 African American patients with treatment resistant hypertension.</p>]]>
	</Description>
	<StudyInEx><![CDATA[
<p>Our sample of 91 affected resistant hypertensive African Americans represents an extreme sampling approach from the upper tail of the distribution of blood pressure response to antihypertensive drugs from a large RCT. We have defined our phenotype as a more extreme version of resistant hypertension: our 91 subjects were all taking 4 or more medications to lower blood pressure and had blood pressure values greater than 140/90 mmHg after four years in the RCT. </p>]]>
	</StudyInEx>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Hypertension"/>
		<Disease vocab_source="MESH" vocab_term="Antihypertensive Agents"/>
		<Disease vocab_source="MESH" vocab_term="Drug Resistance"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Donna Arnett, PhD</AttName>
			<Institution>University of Alabama at Birmingham, Birmingham, AL, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>NHLBI/NHGRI Exome Project</AttName>
			<Institution>National Institutes of Health, Bethesda, MD, USA</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<StudyHistory><![CDATA[
<p>Data are derived from a completed randomized clinical trial wherein patients were randomized to one of four treatment arms and followed prospectively for an average of 4.2 years. About 35% of the trial participants were African American. </p>]]>
	</StudyHistory>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="GRU" longName="General Research Use"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NHLBI</DacName>
      <DacFullName>National Heart, Lung, and Blood Institute DAC</DacFullName>
      <DacEmail>nhlbigeneticdata@nhlbi.nih.gov</DacEmail>
      <DacPhone></DacPhone>
      <DacFax>(301) 480-1455</DacFax>
      <DacUrl>http://grants.nih.gov/grants/gwas</DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000442.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>12</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>no</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000442.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000442.v1.p1" FileName="NHLBIDUC_2010_06_30_Donna_Arnett_UAB_Resistant_Hypertension_in_African_Americans_rev.pdf"/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>General Research Use</ConsentName>
        <ConsentAbbrev>GRU</ConsentAbbrev>
        <UseLimitation>Samples for the Resistant Hypertension in African Americans study are permanently and irreversibly anonymously coded. Based on the consent of these samples, there are no limits on the data use specific to consent. This consent group does not require IRB approval.</UseLimitation>
        <IrbRequired>No</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
